Publications by authors named "P Pavlicek"

Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging. We report the final analysis of a single-arm, phase 2 study evaluating the oral proteasome inhibitor (PI) ixazomib combined with daratumumab and dexamethasone (IDd; NCT03439293). Sixty-one RRMM patients (ixazomib/daratumumab-naïve; 1-3 prior therapies) were enrolled to receive IDd (28-day cycles) until disease progression/unacceptable toxicity.

View Article and Find Full Text PDF

Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG).

View Article and Find Full Text PDF
Article Synopsis
  • Paroxysmal cold hemoglobinuria (PCH) is a rare childhood condition where cold temperatures trigger the breakdown of red blood cells, causing hemoglobin to leak into urine and potentially leading to kidney damage.
  • A study was conducted analyzing the clinical and laboratory data of children diagnosed with PCH-related acute kidney injury at a pediatric hospital in Prague from 2016 to 2022, focusing on three specific cases that required renal replacement therapy.
  • The findings emphasize the link between PCH and kidney disease, suggesting that regular testing of renal function and urine analysis is crucial for all children diagnosed with PCH.
View Article and Find Full Text PDF

Phase measuring deflectometry (PMD) is a proven optical measurement method for measuring the shapes of objects. This method is suitable for measuring the shape of an object with an optically smooth (mirror-like) surface. The measured object is used as a mirror through which the camera observes a defined geometric pattern.

View Article and Find Full Text PDF

We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in relapsed/refractory multiple myeloma patients (RRMM). In total, 240 RRMM patients were treated with Dara-Rd from 2016 to 2022 outside of clinical trials in all major Czech hematology centers. As a reference, 531 RRMM patients treated with Rd were evaluated.

View Article and Find Full Text PDF